Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China.
Eur J Clin Nutr. 2020 Jul;74(7):1001-1008. doi: 10.1038/s41430-019-0500-3. Epub 2019 Sep 25.
Emerging epidemiological studies have assessed the potential relationship between the inflammatory potential of diet measured using the dietary inflammatory index (DII) and the risk of prostate cancer and found inconsistent results. The aim of this study was to systematically evaluate this issue using a meta-analysis approach. A comprehensive literature search of papers published through March 2019 was performed in the PubMed and EMBASE databases. The summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a DerSimonian and Laird random effects model. A categorized analysis and linear and nonlinear dose-response analyses were performed. Ten studies met the inclusion criteria for our meta-analysis. The highest DII score category was associated with a significantly higher risk of prostate cancer than the lowest DII score category (OR = 1.73, 95% CI 1.34-2.23). In the dose-response analysis, the summary OR of prostate cancer for an increment of one unit of the DII was 1.10 (95% CI 1.04-1.17). The sensitivity analysis indicated that exclusion of any single study did not materially alter the pooled risk estimates. Finally, there was no evidence of significant publication bias with Begg's test or with Egger's test. In conclusion, this meta-analysis suggests that an increased DII is related to a higher risk of prostate cancer and that the risk increases by 10.0% per unit of the DII. However, further well-designed prospective trials with larger sample sizes should be performed to validate our preliminary findings.
新出现的一些流行病学研究评估了使用饮食炎症指数（DII）衡量的饮食炎症潜能与前列腺癌风险之间的潜在关系，但研究结果并不一致。本研究旨在通过荟萃分析方法系统地评估这一问题。通过在 PubMed 和 EMBASE 数据库中进行全面的文献检索，检索了截至 2019 年 3 月发表的论文。使用 DerSimonian 和 Laird 随机效应模型估算汇总优势比（OR）和 95%置信区间（CI）。进行了分类分析以及线性和非线性剂量反应分析。符合我们荟萃分析纳入标准的有 10 项研究。DII 评分最高的类别与最低 DII 评分类别相比，前列腺癌的风险显著更高（OR=1.73，95%CI 1.34-2.23）。在剂量反应分析中，DII 每增加一个单位，前列腺癌的汇总 OR 为 1.10（95%CI 1.04-1.17）。敏感性分析表明，排除任何单项研究都不会实质性改变汇总风险估计值。最后，Begg 检验和 Egger 检验均未发现明显的发表偏倚。总之，本荟萃分析表明，DII 增加与前列腺癌风险增加相关，且 DII 每增加一个单位，风险增加 10.0%。然而，应该进行更多设计良好、样本量更大的前瞻性试验，以验证我们的初步发现。
